|
Orthologous residues
|
|
ANXA2 (human): S12‑p, ANXA2 (mouse): S12‑p, ANXA2 (rat): S12‑p, ANXA2 (dog): S12‑p, ANXA2 (cow): S12‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site
|
|
Relevant cell lines - cell types - tissues:
293 (epithelial), HUVEC (endothelial)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
PKCA (human)
|
siRNA inhibition of enzyme, activation of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
plasmin
|
|
|
|
increase
|
|
|
siRNA
|
plasmin
|
|
|
inhibit treatment-induced increase
|
siRNA PKCA
|
|
siRNA
|
plasmin
|
TLR4 (human)
|
|
inhibit treatment-induced increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
intracellular localization, molecular association, regulation
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
S100A10 (human)
|
|
Disrupts
|
protein degradation
|
|
co-immunoprecipitation
|
|